rethinkTHC Search
Menu
Study breakdown

CBD's success in treating epilepsy raises hopes for depression, anxiety, PTSD, addiction, and autism

ReviewModerate evidence
The takeaway

Building on CBD's proven anticonvulsant properties, a growing body of preclinical and clinical evidence suggests it may also help treat depression, anxiety, PTSD, addiction, and autism spectrum disorder.

People interested in CBD for mental health conditions, clinicians following cannabinoid therapeutics, epilepsy patients and families

CBD is FDA-approved for epilepsy with growing evidence for other neuropsychiatric uses

What the researchers found

Strong evidence supports CBD's anticonvulsant properties for epilepsy, and accumulating research suggests promising effects for depression, anxiety, PTSD, addiction, neurodegenerative disorders, and autism. The review highlights contributions from Brazilian researchers who pioneered CBD epilepsy research.

Why it matters

The FDA approval of CBD for epilepsy created a regulatory pathway that could be replicated for other neuropsychiatric conditions if clinical evidence continues to build.

The numbers in context

CBD-based Epidiolex approved for Dravet's syndrome and Lennox-Gastaut syndrome; studies span depression, anxiety, PTSD, addiction, neurodegeneration, and autism

How the study worked

Narrative review of preclinical and clinical data on CBD for epilepsy and neuropsychiatric disorders, with historical context of Brazilian cannabinoid research.

What this study cannot tell us

Much evidence for non-epilepsy conditions remains preclinical. Clinical trials for neuropsychiatric indications are generally smaller and less rigorous than epilepsy trials. Optimal dosing for different conditions is unclear.

How to read the evidence

Narrative review covering strong epilepsy evidence alongside preliminary data for other conditions

When this study was published

Published in 2021. Clinical trials for CBD in neuropsychiatric conditions continue to expand.

The bigger picture

CBD's journey from folk medicine to FDA-approved epilepsy treatment represents a model for how other cannabinoid-based therapeutics might gain mainstream medical acceptance.

Questions still open

  • Which neuropsychiatric condition has the strongest evidence for CBD efficacy beyond epilepsy? Will CBD need different formulations or doses for different psychiatric conditions?

Common questions

Could CBD treat mental health conditions beyond epilepsy?
Preclinical and early clinical evidence suggests CBD may have therapeutic potential for depression, anxiety, PTSD, addiction, and autism. However, the evidence is much stronger for epilepsy than for these other conditions.
How did CBD become an approved epilepsy treatment?
Early research in Brazil demonstrated CBD's anticonvulsant properties in animal models and small human trials. This eventually led to larger clinical trials and the 2018 FDA approval of Epidiolex for Dravet's syndrome and Lennox-Gastaut syndrome.

Read the original research

From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?

Frontiers in psychiatry, 12, 638032

Citation

Bitencourt, Rafael M; Takahashi, Reinaldo N; Carlini, Elisaldo A. (2021). From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?. Frontiers in psychiatry, 12, 638032. https://doi.org/10.3389/fpsyt.2021.638032

Explore the wider topic